NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading TEVA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
TEVA represents a stable investment with moderate risk. The company is currently navigating through a period of mixed financial performance while operating in a favorable healthcare sector backdrop.
The market appears to have priced in a neutral valuation for TEVA, reflecting its cheapness compared to peers. There is a slight expectations gap, indicating that the market may not fully account for potential improvements in execution.
Management has set ambitious revenue and cash flow targets for 2026, but recent results show limited progress toward these goals. The company's recent financial performance has been strong, although there are signs of declining momentum.
The long-term thesis hinges on TEVA's ability to maintain its revenue guidance and achieve its cash flow targets. Additionally, the performance of sector bellwethers like HLN, ZTS, and UTHR will be crucial in determining whether the healthcare sector's positive momentum continues.
Overall, TEVA's position remains stable, but it faces challenges that could impact its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Revenue below this level would signal trouble in meeting the annual target of $16.4-$16.8 billion.
Confirms:Q2 revenue was $3.9 billion or more. This shows progress towards the annual target.
Disproves:Q2 revenue was below $3.9 billion. This shows a continued drop in revenue.
Why it matters: Teva's revenue guidance of $16.4-$16.8 billion shows it is growing steadily. This shows management trusts their plan.
Confirms:Q2 2026 revenue guidance remains within the range of $16.4-$16.8 billion.
Disproves:If guidance drops below $16.4 billion, it raises worries about growth.
Why it matters: The earnings date on July 29 will give details about financial performance.
Confirms one read:Earnings report on July 29 shows strong results and confirms guidance.
Confirms the other:Earnings report on July 29 shows weak results and lowers guidance.
Why it matters: Another earnings beat would build confidence in Teva's recovery. A miss could signal ongoing challenges.
Confirms one read:Q2 earnings exceed analyst expectations as they did in Q1.
Confirms the other:Q2 earnings fall short of analyst expectations.
Why it matters: This target matters for checking how much money Teva makes. Missing it raises worries about how well they run their operations.
Confirms:Adjusted EBITDA is between $5.0 billion and $5.3 billion for 2026.
Disproves:Adjusted EBITDA is less than $5.0 billion.
Why it matters: Reaching this level shows progress towards the $2.0-$2.4 billion target for 2026.
Confirms:Free cash flow reported at $500 million or higher, showing improvement.
Disproves:Free cash flow is still negative or below $500 million. This shows cash problems continue.
Why it matters: This would be a step towards the $5.0-$5.3 billion target for the year.
Confirms:Adjusted EBITDA was $1.2 billion or more. This shows positive momentum.
Disproves:Adjusted EBITDA was below $1.2 billion. This shows challenges with making money.
Why it matters: If healthcare sector growth speeds up, it could benefit Teva's performance.
Confirms:Healthcare sector revenue growth returns to above 10% year over year.
Disproves:Healthcare sector revenue growth stays below 5% year over year.
Why it matters: Free cash flow of $2.0-$2.4 billion shows Teva is financially healthy and efficient.
Confirms:Free cash flow reported between $2.0-$2.4 billion for 2026.
Disproves:Free cash flow below $2.0 billion shows financial difficulties.
